Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms

To read the full story

• Sign In
• Subscribe

Related Article

• Japan Govt to Purchase Another 1 Million Courses of Xocova
  December 14, 2022

• Japan Should Hone Emergency Approval Scheme Based on Xocova Example
  November 28, 2022

• Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
  November 25, 2022

• Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
  November 24, 2022

• Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
  July 27, 2022

• Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
  July 21, 2022

• Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
  July 20, 2022

• Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
  June 23, 2022

• Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
  June 16, 2022

• Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
  May 17, 2022

• Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
  April 25, 2022

• Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
  March 25, 2022

• FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
  March 17, 2022

• Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
  March 7, 2022

• Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
  March 1, 2022

• Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
  February 25, 2022

• Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
  February 16, 2022

• MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
  February 9, 2022

• Shionogi Looks to File COVID Pill in Japan as Early as Next Week
  February 8, 2022

• Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
  February 8, 2022

• Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
  February 1, 2022

• Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
  January 18, 2022

• Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
  January 6, 2022

• Shionogi Launches Global PIII for COVID-19 Vaccine
  December 28, 2021

• Shionogi’s COVID-19 Vaccine Safe and Tolerable, Increases Antibody Titers: Japan PI/II
  December 8, 2021

• Shionogi Kicks Off COVID-19 Booster Trial in Japan
  December 6, 2021

• Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
  November 2, 2021

• Shionogi Launches Japan PII/III for COVID-19 Vaccine
  October 22, 2021

• Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End
  September 30, 2021

• Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
  September 29, 2021

• Secure Domestic Supply of Oral COVID-19 Med: Komeito to Govt
  September 27, 2021

• Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
  September 24, 2021

• Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
  September 24, 2021

• All 60 Subjects Given 1st Dose of Shionogi COVID-19 Jabs in Japan PI/PII
  August 25, 2021

• Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
  December 17, 2020